These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 226215)

  • 1. Alterations in brain opiate receptors in Parkinson's disease.
    Reisine TD; Rossor M; Spokes E; Iversen LL; Yamamura HI
    Brain Res; 1979 Sep; 173(2):378-82. PubMed ID: 226215
    [No Abstract]   [Full Text] [Related]  

  • 2. Opiate and neuroleptic receptor alterations in human schizophrenic brain tissue.
    Reisine TD; Rossor M; Spokes E; Iversen LL; Yamamura HI
    Adv Biochem Psychopharmacol; 1980; 21():443-50. PubMed ID: 6246753
    [No Abstract]   [Full Text] [Related]  

  • 3. Brain enkephalin receptors in Parkinson's disease.
    Rinne UK; Rinne JK; Rinne JO; Laakso K; Tenovuo O; Lönnberg P; Koskinen V
    J Neural Transm Suppl; 1983; 19():163-71. PubMed ID: 6321647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum.
    Guttman M; Seeman P
    J Neural Transm; 1985; 64(2):93-103. PubMed ID: 2934514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease: low density and presynaptic location of D3 dopamine receptors.
    Lee T; Seeman P; Hornykiewicz O; Bilbao J; Deck J; Tourtellotte WW
    Brain Res; 1981 May; 212(2):494-8. PubMed ID: 7225883
    [No Abstract]   [Full Text] [Related]  

  • 6. Developmental relationships between opiate receptors and dopamine in the formation of caudate-putamen patches.
    van der Kooy D
    Brain Res; 1984 Jun; 316(2):300-3. PubMed ID: 6087996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A post-mortem study on striatal dopamine receptors in Parkinson's disease.
    Rinne JO; Laihinen A; Lönnberg P; Marjamäki P; Rinne UK
    Brain Res; 1991 Aug; 556(1):117-22. PubMed ID: 1834312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.
    Kish SJ; Shannak K; Hornykiewicz O
    N Engl J Med; 1988 Apr; 318(14):876-80. PubMed ID: 3352672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mosaic distribution of opiate receptors, parafascicular projections and acetylcholinesterase in rat striatum.
    Herkenham M; Pert CB
    Nature; 1981 Jun; 291(5814):415-8. PubMed ID: 6165892
    [No Abstract]   [Full Text] [Related]  

  • 10. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
    Piggott MA; Marshall EF; Thomas N; Lloyd S; Court JA; Jaros E; Burn D; Johnson M; Perry RH; McKeith IG; Ballard C; Perry EK
    Brain; 1999 Aug; 122 ( Pt 8)():1449-68. PubMed ID: 10430831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consequences of perinatal drug administration on brain development: striatal opiate receptors and dopamine.
    Moon SL
    NIDA Res Monogr; 1985; 62():129-45. PubMed ID: 3001526
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum.
    Kaufman MJ; Madras BK
    Synapse; 1991 Sep; 9(1):43-9. PubMed ID: 1796351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study.
    Nimura T; Yamaguchi K; Ando T; Shibuya S; Oikawa T; Nakagawa A; Shirane R; Itoh M; Tominaga T
    J Neurosurg; 2005 Dec; 103(6):968-73. PubMed ID: 16381182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurotransmitter receptor alterations in Parkinson's disease.
    Reisine TD; Fields JZ; Yamamura HI
    Life Sci; 1977 Aug; 21(3):335-43. PubMed ID: 197361
    [No Abstract]   [Full Text] [Related]  

  • 15. Depletion of AADC activity in caudate nucleus and putamen of Parkinson's disease patients; implications for ongoing AAV2-AADC gene therapy trial.
    Ciesielska A; Samaranch L; San Sebastian W; Dickson DW; Goldman S; Forsayeth J; Bankiewicz KS
    PLoS One; 2017; 12(2):e0169965. PubMed ID: 28166239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F; Fornai F; Blandini F
    Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
    [No Abstract]   [Full Text] [Related]  

  • 17. Dopamine receptor properties in Parkinson's disease and Huntington's chorea evaluated by positron emission tomography using 11C-N-methyl-spiperone.
    Hägglund J; Aquilonius SM; Eckernäs SA; Hartvig P; Lundquist H; Gullberg P; Långström B
    Acta Neurol Scand; 1987 Feb; 75(2):87-94. PubMed ID: 2953165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
    Rinne JO; Ruottinen H; Bergman J; Haaparanta M; Sonninen P; Solin O
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):737-41. PubMed ID: 10567489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
    Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal opioid receptor binding in Parkinson's disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, A [11C]diprenorphine PET study.
    Burn DJ; Rinne JO; Quinn NP; Lees AJ; Marsden CD; Brooks DJ
    Brain; 1995 Aug; 118 ( Pt 4)():951-8. PubMed ID: 7655890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.